Showing results (151-160 of 189) with videos related to
Sort By:
Pageof 19
Journal of Comparative Pathology|October 13, 2009
A review of bovine urothelial tumours and tumour-like lesions of the urinary bladderS Roperto, G Borzacchiello, R Brun, et al.Diseases of the Colon and Rectum|April 29, 1998
Role of Mycobacterium paratuberculosis in Crohn's disease: a prospective, controlled study using polymerase chain reactionW K Clarkston, M E Presti, P F Petersen, et al.Journal of the American Academy of Dermatology|October 16, 2007
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialAlan Menter, Stephen K Tyring, Kenneth Gordon, et al.Journal of Comparative Pathology|July 15, 2009
Ferritin heavy chain (FHC) is up-regulated in papillomavirus-associated urothelial tumours of the urinary bladder in cattleS Roperto, G Borzacchiello, R Brun, et al.Journal of the American Academy of Dermatology|May 17, 2016
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasisPeter C M van de Kerkhof, Christopher E M Griffiths, Kristian Reich, et al.Pediatrics|July 29, 2015
Immunogenicity, Safety, and Tolerability of a Hexavalent Vaccine in InfantsGary S Marshall, Gregory L Adams, Michael L Leonardi, et al.Journal of Endocrinological Investigation|August 27, 2022
Body composition, trabecular bone score and vertebral fractures in subjects with Klinefelter syndromeW Vena, F Carrone, A Delbarba, et al.The Journal of Allergy and Clinical Immunology|April 1, 2014
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasisHoward Sofen, Stacy Smith, Robert T Matheson, et al.JAMA Dermatology|April 9, 2020
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical TrialAndrew Blauvelt, Craig L Leonardi, Melinda Gooderham, et al.JAMA Dermatology|May 14, 2015
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Robert E Kalb, David F Fiorentino, Mark G Lebwohl, et al.Pageof 19